Christopher Heery

Christopher Heery

Company: Arcellx

Job title: Chief Medical Officer


ARC-sparX : A Modular & Universal Cell Platform 11:45 am

An overview of the ARC-sparX platform and how it may be used to address some of the limitations of standard CAR-T cells therapies Modular approach allows for multiple tumour antigen targeting with a universal cell product Control of effector cell and antigen interaction has potential to control expansion kinetics and therefore toxicity profile Combined, this…Read more

day: Day 2 - Track B - Morning

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.